Makoto Kinoshita

Dr. Makoto Kinoshita


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MKMakoto Kinoshita
Makoto Kinoshita
SNShusuke Numata
Shusuke Numata
Atsushi TajimaAtsushi Tajima
Atsushi Tajima
HYHidenaga Yamamori
Hidenaga Yamamori
YYYuka Yasuda
Yuka Yasuda
TOTetsuro Ohmori
Tetsuro Ohmori
Clozapine is an atypical antipsychotic, that is established as the treatment of choice for treatment-resistant schizophrenia (SCZ). To date, no study investigating comprehensive DNA methylation changes in SCZ patients treated with chronic clozapine has been reported. The purpose of the present study is to reveal the effects of clozapine on DNA methylation in treatment-resistant SCZ. We conducted a genome-wide DNA methylation profiling in peripheral leukocytes (485,764 CpG dinucleotides) from treatment-resistant SCZ patients treated with clozapine (n = 21) in a longitudinal study. Significant changes in DNA methylation were observed at 29,134 sites after one year of treatment with clozapine, and these genes were enriched for “cell substrate adhesion” and “cell matrix adhesion” gene ontology (GO) terms. Furthermore, DNA methylation changes in the CREBBP (CREB binding protein) gene were significantly correlated with the clinical improvements. Our findings provide insights into the action of clozapine in treatment-resistant SCZ.

25 June 2015 in Biology of Sex Differences
Verified
Journal Article
Open access
PDF file
MIMasatoshi Inoshita
Masatoshi Inoshita
SNShusuke Numata
Shusuke Numata
Atsushi TajimaAtsushi Tajima
Atsushi Tajima
MKMakoto Kinoshita
Makoto Kinoshita
HUHidehiro Umehara
Hidehiro Umehara
TOTetsuro Ohmori
Tetsuro Ohmori
DNA methylation, which is most frequently the transference of a methyl group to the 5-carbon position of the cytosine in a CpG dinucleotide, plays an important role in both normal development and diseases. To date, several genome-wide methylome studies have revealed sex-biased DNA methylation, yet no studies have investigated sex differences in DNA methylation by taking into account cellular heterogeneity. The aim of the present study was to investigate sex-biased DNA methylation on the autosomes in human blood by adjusting for estimated cellular proportions because cell-type proportions may vary by sex. We performed a genome-wide DNA methylation profiling of the peripheral leukocytes in two sets of samples, a discovery set (49 males and 44 females) and a replication set (14 males and 10 females) using Infinium HumanMethylation450 BeadChips for 485,764 CpG dinucleotides and then examined the effect of sex on DNA methylation with a multiple linear regression analysis after adjusting for age, the estimated 6 cell-type proportions, and the covariates identified in a surrogate variable analysis. We identified differential DNA methylation between males and females at 292 autosomal CpG site loci in the discovery set (Bonferroni-adjusted p < 0.05). Of these 292 CpG sites, significant sex differences were also observed at 98 sites in the replication set (p < 0.05). These findings provided further evidence that DNA methylation may play a role in the differentiation or maintenance of sexual dimorphisms. Our methylome mapping of the effects of sex may be useful to understanding the molecular mechanism involved in both normal development and diseases.

23 July 2014 in NeuroMolecular Medicine
Verified
Journal Article
Closed access
PDF file
MKMakoto Kinoshita
Makoto Kinoshita
SNShusuke Numata
Shusuke Numata
Atsushi TajimaAtsushi Tajima
Atsushi Tajima
KOKazutaka Ohi
Kazutaka Ohi
RHRyota Hashimoto
Ryota Hashimoto
TOTetsuro Ohmori
Tetsuro Ohmori

1 June 2013 in Epigenetics
Verified
Journal Article
Open access
PDF file
MKMakoto Kinoshita
Makoto Kinoshita
SNShusuke Numata
Shusuke Numata
Atsushi TajimaAtsushi Tajima
Atsushi Tajima
SSShinji Shimodera
Shinji Shimodera
IIIssei Imoto
Issei Imoto
TOTetsuro Ohmori
Tetsuro Ohmori
Schizophrenia (SCZ) is a devastating psychiatric disorder with a median lifetime prevalence rate of 0.7–0.8%. Elevated plasma total homocysteine has been suggested as a risk factor for SCZ, and various biological effects of hyperhomocysteinemia have been proposed to be relevant to the pathophysiology of SCZ. As increased attention is paid to aberrant DNA methylation in SCZ, homocysteine is attracting additional interest as a potential key substance. Homocysteine is formed in the methionine cycle, which is involved in one-carbon methyl group-transfer metabolism, and it acts as a methyl donor when it is converted to S-adenosyl-methionine. To date, no studies have examined the relationship between homocysteine and genome-wide DNA methylation in SCZ. We examined the relationship between plasma total homocysteine and DNA methylation patterns in the peripheral leukocytes of patients with SCZ (n = 42) using a quantitative high-resolution DNA methylation array (485,764 CpG sites). Significant homocysteine-related changes in DNA methylation were observed at 1,338 CpG sites that were located across whole gene regions, including promoters, gene bodies and 3′-untranslated regions. Of the 1,338 sites, 758 sites (56.6%) were located in the CpG islands (CGIs) and in the regions flanking CGIs (CGI: 15.8%; CGI shore: 28.2%; CGI shelf: 12.6%), and positive correlations between plasma total homocysteine and DNA methylation were observed predominantly at CpG sites in the CGIs. Our results suggest that homocysteine might play a role in the pathogenesis of SCZ via a molecular mechanism that involves alterations to DNA methylation.

26 July 2015 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
SNShusuke Numata
Shusuke Numata
MKMakoto Kinoshita
Makoto Kinoshita
Atsushi TajimaAtsushi Tajima
Atsushi Tajima
ANAkira Nishi
Akira Nishi
IIIssei Imoto
Issei Imoto
TOTetsuro Ohmori
Tetsuro Ohmori
The results of meta-analyses conducted by previous association studies between total homocysteine and schizophrenia suggest that an elevated total homocysteine level is a risk factor for schizophrenia. However, observational studies have potential limitations, such as confounding and reverse causation. In the present study, we evaluated a causal relationship between plasma total homocysteine and schizophrenia by conducting a Mendelian randomization analysis. We used the MTHFR C677T polymorphism as an instrumental variable, which affects the plasma total homocysteine levels. To calculate the risk estimate for the association of this single nucleotide polymorphism (SNP) with schizophrenia, we conducted a meta-analysis of case–control studies that comprise a total of 11,042 patients with schizophrenia and 14,557 control subjects. We obtained an estimate for the association of this SNP with the plasma total homocysteine levels from a meta-analysis of genome-wide association studies comprising 44,147 individuals. By combining these two estimates, we demonstrated a significant effect of the plasma total homocysteine on schizophrenia risk, representing an OR of 2.15 (95 % CI = 1.39–3.32; p = 5.3 x 10−4) for schizophrenia per 1-SD increase in the natural log-transformed plasma total homocysteine levels. We provided evidence of a causal relationship between the plasma total homocysteine and schizophrenia, and this result will add insight into the pathology and treatment of schizophrenia.

30 November 2018 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
MKMakoto Kinoshita
Makoto Kinoshita
MNMasahito Nakataki
Masahito Nakataki
Ryoma MorigakiRyoma Morigaki
Ryoma Morigaki
SSSatsuki Sumitani
Satsuki Sumitani
SGSatoshi Goto
Satoshi Goto
TOTetsuro Ohmori
Tetsuro Ohmori